&Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

&Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$778K	Buy	13,282 +4,663	+54%	+$255K	﹤0.01%	1573
2026 Q1	$533K	Buy	+8,619	New	+$503K	﹤0.01%	1660

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

&Partners's BMRN Position: Q2 2026 in Review

&Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 54% in Q2 2026, buying an estimated $255K and bringing the position to 13,282 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #1573.

&Partners first reported a position in BMRN in Q1 2026 and has held it in 2 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

&Partners held 13,282 shares of BioMarin Pharmaceuticals worth $778K as of Q2 2026.
&Partners bought 4,663 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $255K.
BioMarin Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #1573 holding.
&Partners first reported a position in BioMarin Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.